Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR   US68827R1086

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/23/2015 06/24/2015 06/25/2015 06/26/2015 06/29/2015 Date
19.99(c) 19.54(c) 19.49(c) 19.38(c) 18.78(c) Last
119 496 118 104 73 139 212 717 197 368 Volume
-0.20% -2.25% -0.26% -0.56% -3.10% Change
More quotes
Financials ($)
Sales 2015 102 M
EBIT 2015 16,8 M
Net income 2015 14,2 M
Debt 2015 -
Yield 2015 -
Sales 2016 127 M
EBIT 2016 26,6 M
Net income 2016 23,2 M
Debt 2016 -
Yield 2016 -
PER 2015 46,37
PER 2016 29,12
Capi. / Sales 2015 6,34x
Capi. / Sales 2016 5,10x
Capitalization 646 M
More Financials
Company
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and wound healing markets.The company operates its business through two segments: Therapeutics and Biosurgery segment.The Therapeutics... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on OSIRIS THERAPEUTICS, INC.
06/12 OSIRIS THERAPEUTICS : Submission of Matters to a Vote of Security Holders, Other..
05/29 OSIRIS THERAPEUTICS : Updates on Establishment of an International Subsidiary
05/27 OSIRIS THERAPEUTICS : Updates on Establishment of an International Subsidiary
05/21 OSIRIS THERAPEUTICS : Evaluates the Establishment of an International Subsidiary
05/21 OSIRIS THERAPEUTICS : Evaluates the Establishment of an International Subsidiary
05/14 OSIRIS THERAPEUTICS : Posts 1Q 2015 Financial Results
05/13 OSIRIS THERAPEUTICS : Posts First Quarter 2015 Financial Results
05/11 OSIRIS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
More news
Sector news : Bio Therapeutic Drugs
06/29DJCelgene to Pay Juno $1 Billion as Part of 10-Year Collaboration
06/29DJCelgene to Pay Juno $1 Billion as Part of 10-Year Collaboration
06/29 Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Mar..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/19 The Long Case For Osiris Therapeutics
05/13 TiGenix's Phase 3 Trial Of Allogeneic Stem Cells Is Likely To Succeed
05/09 Legal Trouble May Be Coming For Osiris' Sales Executives
05/08 Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q1 2015 Results - Earnin..
05/08 Osiris Therapeutics earnings up 333% in Q1


Comments 
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions